Report Ocean has released a market research report on the Alport Syndrome Treatment industry, covering 150+ countries and analyzing over 1,00000 published and forthcoming reports per year. The report, ...

AZN's Daiichi Sankyo-partnered datopotamab deruxtecan fails to show overall survival benefits in a breast cancer study. Stock ...

IDEAYA Bioscience’s rare cancer drug shows benefit in interim Phase II data, with the company announcing the drugs Phase III ...

The NHS is offering autumn Covid boosters to the most vulnerable in October. Many pharmacies also now sell the Covid jab ...

Several launches in 2027 (Amgen, Altimmune), 2028 (Pfizer, Roche, Viking, and Structure), and 2029 (Roche, Viking, ...

The greatest disparity in BC-specific survival was observed in women with HR+ HER2− tumors, with Black women having a 50% ...

The 13 drugs most likely to be chosen for CMS negotiations, according to the study: Ozempic, Rybelsus and Wegovy (semaglutide): Novo Nordisk's treatment for Type 2 diabetes and weight management.

Sigourney Bonner (Human Physiology 2014) is driving change for black people, who are under-represented in cancer research and ...

More than 75% of the cohort started a TNF inhibitor during the selected time frame. For the rest, JAK inhibitors were the ...

Black Diamond Therapeutics and Ideaya Biosciences are mulling over registrational trials for their lead assets after ...